Abstract
Background: ‘Preventability’ is a crucial concept in the literature on adverse drug effects. However, a systematic review of the definitions of preventability of adverse drug effects has suggested that none fits all circumstances. Furthermore, when the reliability of these definitions has been examined they have been found to be imperfect.
Objective: To propose and outline a method for determining the theoretical preventability of an adverse drug effect, based on frameworks for classifying adverse drug reactions — the EIDOS and DoTS methods.
Methods: EIDOS is based on the mechanism of action of the drug. It observes that a drug (an Extrinsic species) causes an adverse effect by interacting with an Intrinsic species that is its target when the two are Distributed together, and that the resulting pathophysiological Outcome (the adverse effect) causes the Sequela (the adverse reaction).
DoTS observes that the Dose-relatedness of the adverse effect compared with the beneficial effect is relevant (determining toxic, collateral, or hypersusceptibility effects), that adverse effects have Time-courses (varying from immediate to delayed), and that there are individual Susceptibility factors.
Results and Discussion: We have elicited many published examples that show that each of these factors in the causation of an adverse drug effect can be adduced to assess its preventability. We have constructed a flowchart that illustrates how the processes can be logically analysed.
Conclusions: This approach suggests methods for devising prospective preventive strategies and for deciding retrospectively whether an adverse reaction in an individual should have been prevented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
A chemical species is “a particular kind of molecule, ion, free radical, etc.” (Oxford English Dictionary)
References
Olivier P, Caron J, Haramburu F, et al. Validation d’une éhelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Thérapie 2005; 60(1): 39–45
Ferner RE, Aronson JK. Preventability of drug-related harms-part I: a systematic review. Drug Saf 2010; 33(11): 985–94
Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf 2010; 33(1): 15–23
Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med. In press
Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115(4): 1048–57
Simat TJ, Kleeberg KK, M;uller B, et al. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999; 467: 469–80
Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 2007; 8(5): 301–14
Montoliu J, Carrera M, Darnell A, et al. Lactic acidosis and Fanconi’s syndrome due to degraded tetracycline. Br Med J (Clin Res Ed) 1981; 283(6306): 1576–7
Flacke W. Treatment of myasthenia gravis. N Engl J Med 1973; 288(1): 27–31
Shaw IC, Rose JWP. Infusion of ifosphamide plus mesna. Lancet 1984; I(8390): 1353–4
Ben Abraham R, Adnet P, Glauber V, et al. Malignant hyperthermia. Postgrad Med J 1998; 74(867): 11–7
Marsh S, Van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009; 85(2): 139–41
Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Curr Opin Mol Ther 2009; 11(3): 231–42
SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359(8): 789–99
McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332(7551): 1177–81
Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991; 164: 1180–5
Martin J, editor. British national formulary. No. 57. Section 4.7.3. Trigeminal neuralgia. London: BMJ Group and RPS Publications, 2009
Slome R. Withdrawal of propranolol and myocardial infarction. Lancet 1973; I(7795): 156
iPledge: committed to pregnancy prevention [online]. Available from URL: https://www.ipledgeprogram.com/PatientInformation.aspx [Accessed 2010 Jul 14]
Peto R. Influence of dose and duration of smoking on lung cancer rates. IARC Sci Publ 1986; (74): 23–33
Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ 1981; 282(6268): 974–6
Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70
Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222–5
Bareggi SR, Tata MR, Guizzaro A, et al. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Int Clin Psychopharmacol 1994; 9(1): 9–16
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326(7404): 1419–23
Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005; 65(4): 525–7
Khoo SH, Bond J, Denning DW. Administering amphotericin B: a practical approach. J Antimicrob Chemother 1994; 33(2): 203–13
Acknowledgements
No sources of funding were used to conduct this study or prepare this manuscript. The authors have no conflicts of interest to declare that are directly relevant to the contents of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aronson, J.K., Ferner, R.E. Preventability of Drug-Related Harms — Part II. Drug-Safety 33, 995–1002 (2010). https://doi.org/10.2165/11538280-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11538280-000000000-00000